4D Molecular Therapeutics (NASDAQ:FDMT) Issues Quarterly Earnings Results

4D Molecular Therapeutics (NASDAQ:FDMT) released its earnings results on Friday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Trading Up 1.1 %

Shares of FDMT stock opened at $4.53 on Friday. The stock has a 50 day moving average of $5.22 and a 200 day moving average of $8.59. The stock has a market cap of $209.41 million, a P/E ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Royal Bank of Canada decreased their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, February 10th. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Finally, Chardan Capital decreased their target price on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.